GlobeNewswire

Agfa-Gevaert: Publication of a transparency notification (Axxioon) – Regulated information

Share

(Article 14 of the law of May 2, 2007 on the disclosure of significant shareholdings)

Mortsel, Belgium – November 20, 2019 – 5.40 p.m. CET 

According to Agfa-Gevaert NV’s bylaws, the threshold as from which a shareholding needs to be disclosed, has been set at 3%, 5% and a multiple of 5%.

In conformity with the Law of May 2, 2007 regarding the disclosure of significant shareholdings in listed companies, Agfa-Gevaert (Euronext: AGFB) discloses the following declaration:

On November 19, 2019, Axxion S.A. has announced that as per November 15, 2019, it holds a stake in Agfa-Gevaert of 5,598,000 shares or 3.26% (denominator is 171,851,042), thus crossing the 3% threshold upwards.

Notifications of important shareholdings to be made according to the Law of
May 2, 2007 or Agfa-Gevaert NV’s bylaws, should be sent to viviane.dictus@agfa.com.

About Agfa
The Agfa-Gevaert Group develops, manufactures and distributes an extensive range of analogue and digital imaging systems and IT solutions, mainly for the printing industry and the healthcare sector, as well as for specific industrial applications.
Agfa’s headquarters and parent company are located in Mortsel, Belgium.
The Agfa-Gevaert Group achieved a turnover of 2,247 million euro in 2018.

Contact:
Viviane Dictus
Director Corporate Communications
tel. ++32 0 3 444 7124
e-mail: viviane.dictus@agfa.com

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Changes in Huhtamaki’s Global Executive Team24.1.2020 09:00:00 CETPress release

HUHTAMÄKI OYJ STOCK EXCHANGE RELEASE 24.1.2020 AT 10:00 Changes in Huhtamaki’s Global Executive Team Arup Basu, (52), PhD (Technology), has been appointed President, Flexible Packaging and a member of Global Executive Team as of February 1, 2020. Arup Basu has been the Managing Director for Huhtamaki's Flexible Packaging business in India since 2017. Before joining Huhtamaki he held several positions in Tata Chemicals Limited (2004-2017), the latest being President and CTO of New Businesses and Innovation Centre. Prior to this he worked at Accenture (1998-2004) as a management consultant and led an R&D department in Indian Aluminium Company Limited (1994-1998). “I wish Arup warmly welcome to the Global Executive Team. It is great to fill this role internally. Arup has demonstrated strong leadership both for business and people with great results, and he has the right experience and characteristics to lead and further develop Flexible Packaging globally,” says Charles Héaulmé, President

Participation Notification by Blackrock Inc.24.1.2020 08:30:00 CETPress release

Brussels, Friday, January 24, 2020, 08h30 CEST --- According to Belgian transparency legislation (Law of May 2, 2007), BlackRock Inc. (55 East 52nd Street, New York, NY, 10055, U.S.A.) recently sent to Solvay a transparency notification indicating that: on January 20, 2020 BlackRock Inc. crossed upwards the 3% statutory threshold for direct voting rights, holding 3,05%. Including equivalent financial instruments, the total voting rights stood at 3.74%. Declarations by BlackRock Inc. are published in the Investor Relations Section of Solvay's website. Attachments Solvay_2020-01-20_Issuer_signed 20200124_Transparency declaration BlackRock-EN

CellaVision AB presenterar bokslutskommunikén för 2019 den femte februari kl. 11:0024.1.2020 08:20:00 CETPressemelding

Informationen lämnades för offentliggörande 2020-01-24 kl 08.20 Den femte februari 2020 klockan 08:20 publicerar CellaVision AB (publ) bokslutskommunikén för 2019. Rapporten kommer att finnas tillgänglig på www.cellavision.se I samband med detta inbjuds analytiker, investerare och media till en audiosänd telefonkonferens samma dag kl 11:00 där VD och koncernchef, Zlatko Rihter, presenterar och kommenterar rapporten. Presentationen sker på engelska via en telefonkonferens eller audiosändning på: https://tv.streamfabriken.com/cellavision-q4-2019 Telefonnummer till konferensen: SE: +46 8 505 583 57 UK: +44 3 333 009 034 US: +1 8 335 268 381 Ingen föranmälan krävs. Vänligen ring in till konferensen 5-10 minuter före utsatt starttid för att underlätta att den startar på fastställd tid. Om CellaVision CellaVision är ett innovativt, globalt medicinteknikföretag som utvecklar och säljer ledande system för rutinanalys av blod och andra kroppsvätskor inom sjukvården. Analyserna utgör ofta viktig

CellaVision AB presents the year-end bulletin for 2019 on February 5 at 11:00 CET24.1.2020 08:20:00 CETPress release

The information was submitted to the public on January 24, 2020 at 8:20 CET CellaVision AB (publ) will publish the year-end bulletin on February 5, 2020 at 8:20 CET. The report will be available at www.cellavision.com In connection with the release of the interim report analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CET where Zlatko Rihter, President & CEO, will present and comment the report. The presentation will be in English via a conference call or audio webcast: https://tv.streamfabriken.com/cellavision-q4-2019 Phone number for the conference: SE: +46 8 505 583 57 UK: +44 3 333 009 034 US: +1 8 335 268 381 No pre-registration is required. Please dial in 5-10 minutes prior to the scheduled start time to facilitate a timely start. About CellaVision CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care ser

Incap Corporation: Greg Grace appointed to Incap’s Management Team24.1.2020 08:00:00 CETPress release

Incap Corporation Stock Exchange Release January 24, 2020, at 9.00 a.m. (EET) Changes in Board/management/auditors Greg Grace appointed to Incap’s Management Team Greg Grace has today been appointed Director, Operations Estonia, and Managing Director of Incap Electronics Estonia, and member of Incap Group’s Management Team. Greg Grace (b. 1971, BA) joined Incap in 2018 and currently holds a position of Director of Business Development at Incap Electronics Estonia. His previous work experiences include the position of CEO, Head of Sales and Member of the Board for Skano Group, Baltic Business Development Manager for Coca-Cola HBC Baltics AS and Managing Director of NSB Kaubanduse AS. “I am pleased to welcome Greg Grace to join Incap’s Management Team. I am also happy to pass him the responsibilities of Estonian operations as new Managing Director of Incap Estonia”, says Otto Pukk, President and CEO of Incap Group. As of January 24, 2020, the Management Team of Incap Group consists of Ot

Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer24.1.2020 07:00:00 CETPress release

Basel, 24 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of disease-free survival (DFS) compared to observation in people with muscle-invasive urothelial cancer (MIUC). Safety for Tecentriq appeared consistent with the known safety profile of the medicine, and no new safety signals were identified. “Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is very difficult, and we are disappointed that we were not able to significantly prolong disease-free survival,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “We remain committed to exploring the potential benefits of immunotherapy for more people with early cancers.” The goal in treating MIUC early is to reduce the risk of the disease recurring or spreading to other parts of the body